filings.toolsItem 16. FORM 10-K SUMMARY
4K characters. Original on sec.gov · Markdown
Item 16. FORM 10-K SUMMARY
**
None.
**SIGNATURES **
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, Abbott Laboratories has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ABBOTT LABORATORIES | ||||
| By | /s/ MILES D. WHITE Miles D. White Chairman of the Board and Chief Executive Officer | |||
| Date: February 22, 2019 |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of Abbott Laboratories on February 22, 2019 in the capacities indicated below.
| /s/ MILES D. WHITE Miles D. White Chairman of the Board, Chief Executive Officer and Director of Abbott Laboratories (principal executive officer) | /s/ BRIAN B. YOOR Brian B. Yoor Executive Vice President, Finance and Chief Financial Officer (principal financial officer) | |
| /s/ ROBERT E. FUNCK Robert E. Funck Senior Vice President, Finance and Controller (principal accounting officer) | ||
| /s/ ROBERT J. ALPERN, M.D. Robert J. Alpern, M.D. Director of Abbott Laboratories | /s/ ROXANNE S. AUSTIN Roxanne S. Austin Director of Abbott Laboratories | |
| /s/ SALLY E. BLOUNT, PH.D. Sally E. Blount, Ph.D. Director of Abbott Laboratories | /s/ MICHELLE A. KUMBIER Michelle A. Kumbier Director of Abbott Laboratories | |
| /s/ EDWARD M. LIDDY Edward M. Liddy Director of Abbott Laboratories | /s/ NANCY MCKINSTRY Nancy McKinstry Director of Abbott Laboratories |
| /s/ PHEBE N. NOVAKOVIC Phebe N. Novakovic Director of Abbott Laboratories | /s/ WILLIAM A. OSBORN William A. Osborn Director of Abbott Laboratories | |
| /s/ SAMUEL C. SCOTT III Samuel C. Scott III Director of Abbott Laboratories | /s/ DANIEL J. STARKS Daniel J. Starks Director of Abbott Laboratories | |
| /s/ JOHN G. STRATTON John G. Stratton Director of Abbott Laboratories | /s/ GLENN F. TILTON Glenn F. Tilton Director of Abbott Laboratories |
**ABBOTT LABORATORIES AND SUBSIDIARIES SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS FOR THE YEARS ENDED DECEMBER 31, 2018, 2017 AND 2016 (in millions of dollars) **
| Allowances for Doubtful Accounts and Product Returns | Balance at Beginning of Year | Provisions/ Charges to Income | Amounts Charged Off and Other Deductions | Balance at End of Year | |||||||||
| 2018 | $ | 294 | $ | 110 | $ | (90 | ) | $ | 314 | ||||
| 2017 | 250 | 105 | (61 | ) | 294 | ||||||||
| 2016 | 337 | 92 | (179 | ) | 250 |
**Report of Independent Registered Public Accounting Firm **
To the Shareholders and Board of Directors of Abbott Laboratories
Opinion on the Financial Statement Schedule
We have audited the consolidated financial statements of Abbott Laboratories and subsidiaries (the Company) as of December 31, 2018 and 2017, and for each of the three years in the period ended December 31, 2018, and have issued our report thereon dated February 22, 2019 (included elsewhere in this Annual Report on Form 10-K). Our audits of the consolidated financial statements included the financial statement schedule listed in Item 15(a)(2) of this Annual Report on Form 10-K (the "schedule"). This schedule is the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's schedule, based on our audits.
In our opinion, the schedule presents fairly, in all material respects, the information set forth therein when considered in conjunction with the consolidated financial statements.
/s/ Ernst & Young LLP
Chicago, Illinois February 22, 2019
Previous: Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES